ACUTE MYELOID LEUKEMIA (AML)

This early-stage study is testing the safety and finding the right dose of a new type of CAR-T cell therapy for adults with advanced CD7-positive blood cancers, specifically acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), that have come …

This study is testing a specific type of stem cell transplant using donated umbilical cord blood to treat patients with serious blood cancers and disorders. The procedure involves high-dose chemotherapy and radiation to wipe out the patient's diseased bone marrow before infusing …

This study is testing a new type of cell therapy for people with advanced solid tumors that have stopped responding to standard treatments. Doctors will analyze a patient's tumor to select a specific target, then infuse specially engineered immune cells (CAR-NK cells) from a heal…

This is a first-in-human study testing a new drug called STX-0712 in patients with advanced forms of blood cancer (CMML and AML) who have no remaining standard treatment options. The main goals are to find a safe dose and see if the drug shows any early signs of fighting the canc…

This study aims to improve outcomes for patients with high-risk blood cancers who receive a stem cell transplant from a partially matched donor. Researchers are testing a modified combination of two drugs (bendamustine and cyclophosphamide) given after the transplant. The goal is…

This early study is testing if a drug called Darzalex Faspro can safely lower harmful antibodies in patients with blood cancers. Lowering these antibodies may allow patients who are currently ineligible to receive a potentially life-saving stem cell transplant from a donor. The s…

This study is testing a new cell therapy for patients whose blood cancers have returned or not responded to standard treatments. Researchers are giving patients specially engineered immune cells, called NK cells, which come from donated cord blood. The goal is to see if these mod…

This early-stage study is testing the safety and initial effectiveness of a new CAR-T cell therapy called A-CAR028 for adults with acute myeloid leukemia (AML) that has returned or not responded to other treatments. The study will enroll up to 20 participants to determine safe do…

This study aims to find the best maintenance therapy to prevent cancer from returning in patients with a specific genetic type of acute myeloid leukemia (AML) who have received a stem cell transplant. Researchers will compare two drugs, gilteritinib and sorafenib, given for two y…

This early-stage study is testing a new drug called APL-4098 in adults with advanced forms of blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Researchers want to find the safest dose and see how well the drug works when given alone or combined …

This large, late-stage trial is testing whether adding an experimental drug called ziftomenib to standard treatments helps people with newly diagnosed acute myeloid leukemia (AML) who have specific genetic mutations. The study will enroll 1300 adults and has two parts: one for ol…

This study is testing whether adding metal detoxification to standard chemotherapy helps control acute myeloid leukemia (AML) better than chemotherapy alone. Researchers will give 140 adults with intermediate or high-risk AML either standard treatment plus metal-removing drugs (C…

This study is testing a three-drug combination (venetoclax pills plus two injectable drugs) to treat adults newly diagnosed with a specific genetic type of acute myeloid leukemia (AML) who are too frail for standard intensive chemotherapy. The main goals are to see how well this …

This study is testing the safety and effectiveness of a new type of CAR-T cell therapy called supCD7 CART for adults with CD7-positive blood cancers that have returned or not responded to standard treatments. The trial will enroll up to 12 patients with either acute myeloid leuke…

This study is testing whether a combination of two drugs, azacitidine and venetoclax, can help get rid of very low levels of leukemia cells that remain after standard chemotherapy in adults with acute myeloid leukemia (AML). The goal is to better prepare patients for a bone marro…

This study is testing whether combining two targeted drugs is safe and helpful for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatment, and who have two specific genetic mutations. Researchers will first find the highest dose of the drug…

This is an early safety study testing a drug called niclosamide, which is normally used to treat tapeworms, in combination with a standard chemotherapy (cytarabine) for children and young adults with acute myeloid leukemia (AML) that has come back or not responded to other treatm…

This program provides early access to the drug venetoclax for patients with certain blood cancers like leukemia and lymphoma before it is fully approved in their country. It is for patients who have no other suitable treatment options and do not qualify for ongoing clinical trial…

This study is testing whether a drug called ivosidenib can help prevent a specific type of leukemia (AML with an IDH1 mutation) from coming back after a patient has received a stem cell transplant. About 75 participants will be randomly assigned to receive either the study drug o…

This study aims to understand how adult patients with acute myeloid leukemia (AML) are treated in real-world settings outside of clinical trials. It will follow 5,000 patients in France to document the treatments they receive and track their long-term survival over up to 10 years…

This study is collecting information about how patients with blood cancers and disorders respond to stem cell transplants in the high-altitude Tibetan region. Researchers are enrolling 1000 patients and their donors to track treatment patterns, recovery times, survival rates, and…

This study is creating a large registry to track adults with acute myeloid leukemia (AML) and related blood cancers in Germany and Austria. Researchers will collect detailed information about patients' disease characteristics, treatments, and outcomes over up to 10 years. The goa…